CD8A and neoplasm: Although preclinical findings strongly suggest an ability of epigenetic modulators to facilitate an influx of T cells into the tumor microenvironment [43], we did not observe an increase in intratumoral CD8+ T cells following treatment with azacitidine plus epacadostat and pembrolizumab, irrespective of treatment sequencing.